Daniela Rivera-Pérez
A5076654685- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Viral gastroenteritis research and epidemiology
- Neonatal Respiratory Health Research
- vaccines and immunoinformatics approaches
- Immune responses and vaccinations
- Viral Infections and Vectors
- COVID-19 Impact on Reproduction
- Thyroid Disorders and Treatments
- Influenza Virus Research Studies
- Immune Response and Inflammation
- Immune Cell Function and Interaction
- Heme Oxygenase-1 and Carbon Monoxide
Millennium Institute on Immunology and Immunotherapy
2019-2024
Pontificia Universidad Católica de Chile
2019-2024
The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine with promising safety and immunogenicity profiles. This article reports results obtained for healthy Chilean adults aged ≥18 years in phase 3 clinical trial.Volunteers randomly received doses or placebo, separated by weeks. A total 434 volunteers were enrolled, 397 18-59 37 ≥60 years. Solicited unsolicited adverse...
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible of current pandemic ongoing all around world. Since its discovery in 2019, several circulating variants have emerged and some them are associated with increased infections death rate. Despite genetic differences among these variants, vaccines approved for human use shown a good immunogenic protective response against them. In Chile, over 70% vaccinated population immunized CoronaVac, an...
Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are actively carried out around the world. Several vaccines currently approved for emergency use in population, while ongoing studies continue provide information on their safety and effectiveness. CoronaVac is an inactivated SARS-CoV-2 vaccine with a good immunogenicity profile as seen phase 1, 2, 3 clinical trials world, effectiveness of 65.9% symptomatic cases. Although vaccination...
The ongoing COVID-19 pandemic has had a significant impact worldwide, with an incommensurable social and economic burden. rapid development of safe protective vaccines against this disease is global priority. CoronaVac vaccine prototype based on inactivated SARS-CoV-2, which shown promising safety immunogenicity profiles in pre-clinical studies phase 1/2 trials China. To day, four 3 clinical are Brazil, Indonesia, Turkey, Chile. This article reports the results obtained subgroup participants...
CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 4 weeks after two doses CoronaVac; these were significantly reduced at 6 to 8 months doses. Here, we report effect a booster dose on anti-SARS-CoV-2 immune response generated against variants concern (VOCs), Delta Omicron, in adults participating phase III clinical trial Chile. Volunteers immunized with...
Summary Current treatments for systemic autoimmune diseases partially improve the health of patients displaying low pharmacological efficacy and immunosuppression. Here, therapeutic potential transferring tolerogenic dendritic cells (tolDCs) generated with heme‐oxygenase inductor cobalt (III) protoporphyrin IX (CoPP), dexamethasone rosiglitazone treatment autoimmunity was evaluated in two murine models lupus erythematosus (SLE), MRL‐Fas lpr NZM2410 mice. Dendritic treated ex vivo these drugs...
Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response pediatric population are scarce. The inactivated vaccine CoronaVac has shown to be safe and immunogenic a phase 1/2 trial cohort China. Here, we report interim safety immunogenicity results of 3 for healthy children adolescents Chile. Participants 17 years old received two doses 4-week interval until 31 December 2021....
BackgroundThe Omicron variant has challenged the control of COVID-19 pandemic due to its immuno-evasive properties. The administration a booster dose SARS-CoV-2 vaccine showed positive effects in immunogenicity against SARS-CoV-2, effect that is even enhanced after second booster.MethodsDuring phase-3 clinical trial, we evaluated CoronaVac®, an inactivated administered 6 months first booster, neutralization (n = 87). In parallel, cellular immunity 45) was analyzed stimulated peripheral...
The human respiratory syncytial virus (hRSV) constitutes a major health burden, causing millions of hospitalizations in children under five years old worldwide due to acute lower tract infections. Despite decades research, licensed vaccines prevent hRSV are not available. Development against targeting young infants requires ruling out potential vaccine-enhanced disease presentations. To achieve this goal, vaccine testing proper animal models is essential. A recombinant BCG that expresses the...
Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac an inactivated severe acute respiratory syndrome 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials China, Brazil, Indonesia, Turkey, Chile. Methods: This study randomized, multicenter, controlled phase 3 trial healthy Chilean adults aged ≥18 years. Volunteers received two doses...
Abstract Background CoronaVac ® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- four-weeks after two doses , but are reduced at six to eight months doses. Here we report effect a booster dose on anti-SARS-CoV-2 immune response generated against variants concern (VOC) Delta Omicron in adults participating phase 3 clinical trial Chile. Methods Volunteers immunized...
Abstract Background Multiple vaccines against SARS-CoV-2 have been evaluated in clinical trials, but very few include the pediatric population. The inactivated vaccine CoronaVac ® has shown to be safe and immunogenic a phase 1/2 trial cohort China. This study is an interim safety immunogenicity report of 3 for healthy children adolescents Chile. Methods Participants aged 17 years old received two doses four-week interval. Local systemic adverse reactions were registered 699 participants that...
Summary The SARS-CoV-2 Omicron variant has challenged the control of COVID-19 pandemic even in highly vaccinated countries. While a second booster mRNA vaccines improved immunity against SARS-CoV-2, humoral and cellular responses induced by an inactivated vaccine have not been studied. In context phase 3 clinical study, we report that CoronaVac ® increased neutralizing response ancestral virus yet showed poor neutralization variant. Additionally, isolated PBMCs displayed equivalent...
Background Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of Omicron variant, its subvariants, and immune response dynamics naturally infected with virus. Methods Twelve subjects between 3-17 years old (yo), vaccinated two doses CoronaVac ® , were followed diagnosed as breakthrough cases starting 14 days after receiving second dose. Total IgGs different proteins neutralizing capacity these antibodies measured in plasma. The...
Maternal thyroid hormones (THs) are essential for the appropriate development of fetus and especially brain. Recently, some studies have shown that THs deficiency can also alter immune system progeny their ability to mount an response against infectious agents. In this study, we evaluated whether adult mice gestated under hypothyroxinemia (Hpx) showed altered infection with human metapneumovirus (hMPV). We observed female Hpx higher clinical scores after seven days hMPV infection. Besides,...
Abstract Background The development of vaccines to control the COVID-19 pandemic progression is a worldwide priority. CoronaVac ® an inactivated SARS-CoV-2 vaccine approved for emergency use with robust efficacy and immunogenicity data reported in trials China, Brazil, Indonesia, Turkey, Chile. Methods This study randomized, multicenter, controlled phase 3 trial healthy Chilean adults aged ≥18 years. Volunteers received two doses separated by (0-14 schedule) or four weeks (0-28 schedule)....